Myocardial Infarction - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 357 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Myocardial Infarction - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Myocardial Infarction - Pipeline Review, H2 2016', provides an overview of the Myocardial Infarction pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction
- The report reviews pipeline therapeutics for Myocardial Infarction by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Myocardial Infarction therapeutics and enlists all their major and minor projects
- The report assesses Myocardial Infarction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Myocardial Infarction

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
Introduction 6
Myocardial Infarction Overview 7
Therapeutics Development 8
Myocardial Infarction - Therapeutics under Development by Companies 10
Myocardial Infarction - Therapeutics under Investigation by Universities/Institutes 15
Myocardial Infarction - Pipeline Products Glance 17
Myocardial Infarction - Products under Development by Companies 21
Myocardial Infarction - Products under Investigation by Universities/Institutes 27
Myocardial Infarction - Companies Involved in Therapeutics Development 29
Myocardial Infarction - Therapeutics Assessment 87
Drug Profiles 104
Myocardial Infarction - Dormant Projects 319
Myocardial Infarction - Discontinued Products 328
Myocardial Infarction - Product Development Milestones 329
Appendix 343

List of Tables

Number of Products under Development for Myocardial Infarction, H2 2016 21
Number of Products under Development for Myocardial Infarction - Comparative Analysis, H2 2016 22
Number of Products under Development by Companies, H2 2016 23
Number of Products under Development by Companies, H2 2016 (Contd..1) 24
Number of Products under Development by Companies, H2 2016 (Contd..2) 25
Number of Products under Development by Companies, H2 2016 (Contd..3) 26
Number of Products under Development by Companies, H2 2016 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H2 2016 29
Comparative Analysis by Late Stage Development, H2 2016 30
Comparative Analysis by Clinical Stage Development, H2 2016 31
Comparative Analysis by Early Stage Development, H2 2016 32
Comparative Analysis by Unknown Stage Development, H2 2016 33
Products under Development by Companies, H2 2016 34
Products under Development by Companies, H2 2016 (Contd..1) 35
Products under Development by Companies, H2 2016 (Contd..2) 36
Products under Development by Companies, H2 2016 (Contd..3) 37
Products under Development by Companies, H2 2016 (Contd..4) 38
Products under Development by Companies, H2 2016 (Contd..5) 39
Products under Investigation by Universities/Institutes, H2 2016 40
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 41
Myocardial Infarction - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 42
Myocardial Infarction - Pipeline by Asterias Biotherapeutics, Inc., H2 2016 43
Myocardial Infarction - Pipeline by AstraZeneca Plc, H2 2016 44
Myocardial Infarction - Pipeline by Athersys, Inc., H2 2016 45
Myocardial Infarction - Pipeline by Bayer AG, H2 2016 46
Myocardial Infarction - Pipeline by Bharat Biotech International Limited, H2 2016 47
Myocardial Infarction - Pipeline by BioCardia, Inc., H2 2016 48
Myocardial Infarction - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016 49
Myocardial Infarction - Pipeline by Capricor Therapeutics, Inc., H2 2016 50
Myocardial Infarction - Pipeline by CellProthera, H2 2016 51
Myocardial Infarction - Pipeline by Celyad SA, H2 2016 52
Myocardial Infarction - Pipeline by Chrysalis BioTherapeutics, Inc., H2 2016 53
Myocardial Infarction - Pipeline by Compugen Ltd., H2 2016 54
Myocardial Infarction - Pipeline by CSL Limited, H2 2016 55
Myocardial Infarction - Pipeline by Cynata Therapeutics Limited, H2 2016 56
Myocardial Infarction - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016 57
Myocardial Infarction - Pipeline by FibroGen, Inc., H2 2016 58
Myocardial Infarction - Pipeline by Hemostemix Ltd, H2 2016 59
Myocardial Infarction - Pipeline by Hope Pharmaceuticals, Inc., H2 2016 60
Myocardial Infarction - Pipeline by Human Stem Cells Institute, H2 2016 61
Myocardial Infarction - Pipeline by HUYA Bioscience International, LLC, H2 2016 62
Myocardial Infarction - Pipeline by Inotrem S.A., H2 2016 63
Myocardial Infarction - Pipeline by Juventas Therapeutics, Inc., H2 2016 64
Myocardial Infarction - Pipeline by Laboratoires Pierre Fabre SA, H2 2016 65
Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 66
Myocardial Infarction - Pipeline by LegoChem Biosciences, Inc, H2 2016 67
Myocardial Infarction - Pipeline by LG Life Science LTD., H2 2016 68
Myocardial Infarction - Pipeline by Medestea Research & Production S.p.A., H2 2016 69
Myocardial Infarction - Pipeline by Mesoblast Limited, H2 2016 70
Myocardial Infarction - Pipeline by miRagen Therapeutics, Inc., H2 2016 71
Myocardial Infarction - Pipeline by Moderna Therapeutics Inc, H2 2016 72
Myocardial Infarction - Pipeline by Navya Biologicals Pvt Ltd, H2 2016 73
Myocardial Infarction - Pipeline by NeuroVive Pharmaceutical AB, H2 2016 74
Myocardial Infarction - Pipeline by New World Laboratories, Inc., H2 2016 75
Myocardial Infarction - Pipeline by Novartis AG, H2 2016 76
Myocardial Infarction - Pipeline by NuvOx Pharma LLC, H2 2016 77
Myocardial Infarction - Pipeline by Omeros Corporation, H2 2016 78
Myocardial Infarction - Pipeline by Opsona Therapeutics Limited, H2 2016 79
Myocardial Infarction - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 80
Myocardial Infarction - Pipeline by Pfizer Inc., H2 2016 81
Myocardial Infarction - Pipeline by Pharmathen Pharmaceuticals S.A., H2 2016 82
Myocardial Infarction - Pipeline by Primary Peptides, Inc., H2 2016 83
Myocardial Infarction - Pipeline by Quantum Genomics SA, H2 2016 84
Myocardial Infarction - Pipeline by Quark Pharmaceuticals, Inc., H2 2016 85
Myocardial Infarction - Pipeline by Recardio GmbH, H2 2016 86
Myocardial Infarction - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016 87
Myocardial Infarction - Pipeline by Serodus ASA, H2 2016 88
Myocardial Infarction - Pipeline by Silver Creek Pharmaceuticals, Inc., H2 2016 89
Myocardial Infarction - Pipeline by Stealth BioTherapeutics Inc., H2 2016 90
Myocardial Infarction - Pipeline by Stemedica Cell Technologies, Inc., H2 2016 91
Myocardial Infarction - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2016 92
Myocardial Infarction - Pipeline by Targazyme, Inc., H2 2016 93
Myocardial Infarction - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 94
Myocardial Infarction - Pipeline by TiGenix NV, H2 2016 95
Myocardial Infarction - Pipeline by Vicore Pharma AB, H2 2016 96
Myocardial Infarction - Pipeline by XBiotech Inc, H2 2016 97
Myocardial Infarction - Pipeline by Yuyu Pharma, Inc., H2 2016 98
Myocardial Infarction - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 99
Assessment by Monotherapy Products, H2 2016 100
Assessment by Combination Products, H2 2016 101
Number of Products by Stage and Target, H2 2016 103
Number of Products by Stage and Mechanism of Action, H2 2016 108
Number of Products by Stage and Route of Administration, H2 2016 114
Number of Products by Stage and Molecule Type, H2 2016 116
Myocardial Infarction - Dormant Projects, H2 2016 332
Myocardial Infarction - Dormant Projects (Contd..1), H2 2016 333
Myocardial Infarction - Dormant Projects (Contd..2), H2 2016 334
Myocardial Infarction - Dormant Projects (Contd..3), H2 2016 335
Myocardial Infarction - Dormant Projects (Contd..4), H2 2016 336
Myocardial Infarction - Dormant Projects (Contd..5), H2 2016 337
Myocardial Infarction - Dormant Projects (Contd..6), H2 2016 338
Myocardial Infarction - Dormant Projects (Contd..7), H2 2016 339
Myocardial Infarction - Dormant Projects (Contd..8), H2 2016 340
Myocardial Infarction - Discontinued Products, H2 2016 341